Abstract
We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with
Original language | English |
---|---|
Pages (from-to) | 2279-2288 |
Number of pages | 10 |
Journal | European Journal of Cancer |
Volume | 38 |
Issue number | 17 |
DOIs | |
Publication status | Published - Nov 2002 |
Keywords
- Adjuvant therapy
- Breast cancer
- CMF
- Epirubicin
- Randomised study
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology